Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

van Engelen

Showing results (111-120 of 831) with videos related to

Pageof 84
Sort By:
Regulatory Toxicology and Pharmacology : RTP|November 20, 2012
First tier modeling of consumer dermal exposure to substances in consumer articles under REACH: a quantitative evaluation of the ECETOC TRA for consumers toolJ E Delmaar, B G H Bokkers, W ter Burg, et al.
The Cochrane Database of Systematic Reviews|December 7, 2019
Strength training and aerobic exercise training for muscle diseaseNicoline Bm Voet, Elly L van der Kooi, Baziel Gm van Engelen, et al.
Regulatory Toxicology and Pharmacology : RTP|May 18, 2005
Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop reportH R Pohl, J G M van Engelen, J Wilson, et al.
Brain : a Journal of Neurology|March 29, 2000
The natural history of hereditary neuralgic amyotrophy in the Dutch population: two distinct types?N van Alfen, B G van Engelen, J W Reinders, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|April 14, 2012
Automated measurement of MIB-1 positive area as an alternative to counting in follicular lymphomaJeroen A W M van der Laak, Nienke van Engelen, Maarten Melissen, et al.
Annals of Neurology|August 5, 2004
Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiencyMette C ØRngreen, Mette G Nørgaard, Massimo Sacchetti, et al.
Epilepsy Research|December 1, 1994
Immunoglobulin treatment in epilepsy, a review of the literatureB G van Engelen, W O Renier, C M Weemaes, et al.
Critical Care Clinics|November 19, 2017
Biomarkers in SepsisTjitske S R van Engelen, Willem Joost Wiersinga, Brendon P Scicluna, et al.
The Netherlands Journal of Medicine|December 12, 2012
MIDD or MELAS : that's not the question MIDD evolving into MELAS : a severe phenotype of the m.3243A>G mutation due to paternal co-inheritance of type 2 diabetes and a high heteroplasmy levelH M de Wit, H J Westeneng, B G M van Engelen, et al.
Disability and Rehabilitation|July 4, 2012
Research priorities of patients with neuromuscular diseaseChristi J Nierse, Tineke A Abma, Anja M C Horemans, et al.
Pageof 84

Showing results (111-120 of 831) with videos related to

Sort By:
Pageof 84
Regulatory Toxicology and Pharmacology : RTP|November 20, 2012
First tier modeling of consumer dermal exposure to substances in consumer articles under REACH: a quantitative evaluation of the ECETOC TRA for consumers toolJ E Delmaar, B G H Bokkers, W ter Burg, et al.
The Cochrane Database of Systematic Reviews|December 7, 2019
Strength training and aerobic exercise training for muscle diseaseNicoline Bm Voet, Elly L van der Kooi, Baziel Gm van Engelen, et al.
Regulatory Toxicology and Pharmacology : RTP|May 18, 2005
Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop reportH R Pohl, J G M van Engelen, J Wilson, et al.
Brain : a Journal of Neurology|March 29, 2000
The natural history of hereditary neuralgic amyotrophy in the Dutch population: two distinct types?N van Alfen, B G van Engelen, J W Reinders, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|April 14, 2012
Automated measurement of MIB-1 positive area as an alternative to counting in follicular lymphomaJeroen A W M van der Laak, Nienke van Engelen, Maarten Melissen, et al.
Annals of Neurology|August 5, 2004
Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiencyMette C ØRngreen, Mette G Nørgaard, Massimo Sacchetti, et al.
Epilepsy Research|December 1, 1994
Immunoglobulin treatment in epilepsy, a review of the literatureB G van Engelen, W O Renier, C M Weemaes, et al.
Critical Care Clinics|November 19, 2017
Biomarkers in SepsisTjitske S R van Engelen, Willem Joost Wiersinga, Brendon P Scicluna, et al.
The Netherlands Journal of Medicine|December 12, 2012
MIDD or MELAS : that's not the question MIDD evolving into MELAS : a severe phenotype of the m.3243A>G mutation due to paternal co-inheritance of type 2 diabetes and a high heteroplasmy levelH M de Wit, H J Westeneng, B G M van Engelen, et al.
Disability and Rehabilitation|July 4, 2012
Research priorities of patients with neuromuscular diseaseChristi J Nierse, Tineke A Abma, Anja M C Horemans, et al.
Pageof 84